BioCentury
ARTICLE | Financial News

Sinovac going private

June 26, 2017 8:30 PM UTC

Sinovac Biotech Ltd. (NASDAQ:SVA) said it will be acquired by an investor syndicate led by Chairman, President and CEO Weidong Yin and SAIF Partners for $7 per share, or about $401.8 million. Other investors include C-Bridge Capital, Advantech Capital and Vivo Capital. The deal is expected to close this year.

The price is a 23% premium to Sinovac’s close of $5.70 on June 23, before the deal was announced. The deal is subject to shareholder approval...

BCIQ Company Profiles

Sinovac Biotech Ltd.